The estimated Net Worth of Andrew D. Jones is at least 61.1 千$ dollars as of 3 December 2021. Mr. Jones owns over 45,455 units of Novabay Pharmaceuticals Inc stock worth over 61,092$ and over the last 4 years he sold NBY stock worth over 0$. In addition, he makes 0$ as Chief Financial Officer、 Treasurer at Novabay Pharmaceuticals Inc.
Andrew has made over 1 trades of the Novabay Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 45,455 units of NBY stock worth 20,000$ on 3 December 2021.
The largest trade he's ever made was buying 45,455 units of Novabay Pharmaceuticals Inc stock on 3 December 2021 worth over 20,000$. On average, Andrew trades about 9,091 units every 0 days since 2020. As of 3 December 2021 he still owns at least 127,461 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Mr. Jones stock trades at the bottom of the page.
Andrew Jones serves as Chief Financial Officer, Treasurer of the Company. He served as the Vice President of Finance of MyoScience, Inc., a commercial stage company that produced disposable pain management devices, from July 2017 until its acquisition by Pacira BioSciences, Inc. (Nasdaq: PCRX) in August 2019, during which time he was responsible for all financial, accounting, investor relations and risk management functions as well as leading debt and equity fundraising. Mr. Jones has served as Controller for various public and private life sciences companies including Armetheon, Inc. (May 2015 to July 2017), Asante Solutions, Inc. (Oct. 2014 to May 2015) and Genelabs Technologies, Inc. (then, Nasdaq: GNLB) (2005 to 2009) and began his career with PriceWaterhouseCoopers. Mr. Jones received a B.S. degree in Business Administration from the University of Washington in Seattle.
Andrew Jones is 50, he's been the Chief Financial Officer、 Treasurer of Novabay Pharmaceuticals Inc since 2020. There are 5 older and 4 younger executives at Novabay Pharmaceuticals Inc. The oldest executive at Novabay Pharmaceuticals Inc is Paul Freiman, 81, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over 3,799,939$ worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth 26,237,091$ . The most active insiders traders include Pharma (Singapore) Pte. Ltd...、Pioneer Pharma Holdings Ltd...、Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of 127,779$. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth 411$.
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include: